Clinical trial
Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia
NCT00040105 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00040105 |
|---|---|
| Title | Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia |
| Official title | Phase I Study of Zarnestra (R115777.USA30) and Gleevec (Imatinib Mesylate) in Chronic Phase Chronic Myelogenous Leukemia (CML) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Myeloid, Chronic |
| Intervention type | Drug |
| Interventions | Zarnestra (R115777), Gleevec (Imatinib mesylate) |
| Enrollment | 26 |
| Start date | Oct 1, 2002 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Jun 21, 2002 |
| Last update posted | Aug 1, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: